| Literature DB >> 23457421 |
Afrooz Zirakzadeh1, Manuela A Groß, Yaping Wang, Kurt Mereiter, Felix Spindler, Walter Weissensteiner.
Abstract
A total of four biferrocene-based Walphos-type ligands have been synthesized, structurally characterized, and tested in the rhodium-, ruthenium- and iridium-catalyzed hydrogenation of alkenes and ketones. Negishi coupling conditions allowed the biferrocene backbone of these diphosphine ligands to be built up diastereoselectively from the two nonidentical and nonracemic ferrocene fragments (R)-1-(N,N-dimethylamino)ethylferrocene and (SFc)-2-bromoiodoferrocene. The molecular structures of (SFc)-2-bromoiodoferrocene, the coupling product, two ligands, and the two complexes ([PdCl2(L)] and [RuCl(p-cymene)(L)]PF6) were determined by X-ray diffraction. The structural features of complexes and the catalysis results obtained with the newly synthesized biferrocene-based ligands were compared with those of the corresponding Walphos ligands.Entities:
Year: 2013 PMID: 23457421 PMCID: PMC3584622 DOI: 10.1021/om3012147
Source DB: PubMed Journal: Organometallics ISSN: 0276-7333 Impact factor: 3.876
Chart 1
Scheme 1
Scheme 2
Figure 1Molecular structures of (SFc)-2, (R,SFc,RFc)-3·BH3, (R,SFc,RFc)-16, (R,SFc,RFc)-17, [PdCl2(15)] (molecule 1), and [RuCl(p-cymene)(15)]PF6 showing 50% displacement ellipsoids. Hydrogen atoms and PF6– are omitted for clarity.
Scheme 3
Scheme 4
Chart 2
Figure 2Superpositions of the molecular structures of [PdCl2(15)] and [PdCl2(SL-W002-1)] (left) and of [RuCl(p-cymene)(15)]PF6 with [RuCl(p-cymene)(SL-W002-1)]PF6 (right; only the cations of the ruthenium complexes are shown). Ligand 15 is shown in green and SL-W002-1 in blue. In both cases the Cp carbons C1–C5 and Fe1 are superimposed.
Chart 3Substrates Used for Catalyst Screening
Selected High-Throughput Screening Results Obtained with Ligands (R,SFc,RFc)-14–17 in the Rhodium-Catalyzed Hydrogenation of Double Bondsa
| entry | substrate | metal precursor | ligand | solvent | conversn, % | ee, % |
|---|---|---|---|---|---|---|
| 1 | MAC | [Rh(NBD)Cl]2 | THF | >99 | 47 | |
| 2 | MAC | [Rh(NBD)Cl]2 | THF | >99 | ||
| 3 | MAC | [Rh(NBD)2]BF4 | MeOH | >99 | ||
| 4 | MAC | [Rh(NBD)Cl]2 | THF | 18 | ||
| 5 | MAC | [Rh(NBD)2]BF4 | MeOH | >99 | ||
| 6 | MAA | [Rh(NBD)Cl]2 | THF | >99 | 59 | |
| 7 | MAA | [Rh(NBD)2]BF4 | MeOH | >99 | 51 | |
| 8 | MAA | [Rh(NBD)2]BF4 | MeOH | >99 | ||
| 9 | MAA | [Rh(COD)2]O3SCF3 | THF | >99 | ||
| 10 | MAA | [Rh(NBD)2]BF4 | MeOH | >99 | 76 | |
| 11 | DMI | [Rh(NBD)Cl]2 | THF | 99 | 31 | |
| 12 | DMI | [Rh(NBD)2]BF4 | MeOH | 99 | 26 | |
| 13 | DMI | [Rh(NBD)2]BF4 | MeOH | >99 | 77 | |
| 14 | DMI | [Rh(NBD)Cl]2 | THF | 98 | 54 | |
| 15 | MCA | [Rh(NBD)Cl]2 | THF | >99 | 47 | |
| 16 | MCA | [Rh(NBD)Cl]2 | THF | 80 | ||
| 17 | MCA | [Rh(NBD)2]BF4 | MeOH | >99 | 46 | |
| 18 | MCA | [Rh(NBD)2]BF4 | MeOH | >99 | 61 | |
| 19 | AllylOH | [Rh(NBD)Cl]2 | THF | >99 | 73 | |
| 20 | AllylOH | [Rh(NBD)Cl]2 | THF | >99 | 40 | |
| 21 | AllylOH | [Rh(COD)2]O3SCF3 | THF | >99 | ||
| 22 | AllylOH | [Rh(COD)2]O3SCF3 | THF | >99 | ||
| 23 | EAAC | [Rh(NBD)Cl]2 | THF | >99 | 50 | |
| 24 | EAAC | [Rh(NBD)2]BF4 | MeOH | >99 | 40 | |
| 25 | EAAC | [Rh(NBD)Cl]2 | THF | 60 | 42 | |
| 26 | EAAC | [Rh(NBD)Cl]2 | THF | 86 | 49 | |
| 27 | DHNAA | [Rh(NBD)Cl]2 | THF | >99 | 19 | |
| 28 | DHNAA | [Rh(NBD)Cl]2 | THF | 81 | 24 | |
| 29 | DHNAA | [Rh(NBD)Cl]2 | THF | 16 | 28 | |
| 30 | DHNAA | [Rh(NBD)2]BF4 | MeOH | >99 | 22 | |
| 31 | MPG | [Rh(COD)2]O3SCF3 | THF | 99 | 51 | |
| 32 | MPG | [Rh(NBD)Cl]2 | THF | 99 | 46 | |
| 33 | MPG | [Rh(NBD)Cl]2 | THF | >99 | 50 | |
| 34 | MPG | [Rh(NBD)Cl]2 | THF | 99 | 44 |
Reaction conditions: substrate, 41.67 μmol; catalyst, 1.67 μmol; catalyst loading S/C, 25; Vtotal, 500 μL.
Comparison of Hydrogenation Data Obtained with Use of Walphos and Biferrocene Ligands
| entry | substrate | precursor | solvent | Walphos ligand | S/C | conversn, % | ee, % | BiFc ligand | S/C | conversn, % | ee, % | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MAC | [Rh(NBD)2]BF4 | MeOH | 20 | 1 | W002-2 | 100 | 100 | 25 | 100 | 21 | ||
| 2 | MAC | [Rh(NBD)2]BF4 | MeOH | 20 | 1 | W001-1 | 100 | 100 | 63 | 25 | 100 | ||
| 3 | MAA | [Rh(NBD)2]BF4 | MeOH | 20 | 1 | W002-2 | 100 | 100 | 96 | 25 | 100 | 51 | |
| 4 | MAA | [Rh(NBD)2]BF4 | MeOH | 20 | 1 | W001-1 | 100 | 100 | 25 | 100 | |||
| 5 | DMI | [Rh(NBD)2]BF4 | MeOH | 20 | 1 | W002-2 | 100 | 100 | 25 | 99 | 26 | ||
| 6 | DMI | [Rh(NBD)2]BF4 | MeOH | 20 | 1 | W001-1 | 100 | 100 | 52 | 25 | 100 | ||
| 7 | MCA | [Rh(NBD)2]BF4 | MeOH | 20 | 20 | W002-2 | 100 | 99 | 62 | 25 | 100 | 40 | |
| 8 | MCA | [Rh(NBD)2]BF4 | MeOH | 20 | 20 | W001-1 | 100 | 100 | 25 | 100 | 46 | ||
| 9 | MCA | [RhCl(NBD)]2 | THF | 20 | 20 | W002-2 | 100 | 11 | n.d. | 100 | 19 | 76 | |
| 10 | MCA | [RhCl(NBD)]2 | THF | 20 | 20 | W002-2 | 25 | 14 | n.d. | 25 | 63 | ||
| 11 | PCA | [Rh(NBD)2]BF4 | MeOH | 20 | 50 | W002-2 | 100 | 77 | 100 | 100 | 29 | ||
| 12 | PCA | [Rh(NBD)2]BF4 | MeOH | 20 | 50 | W001-1 | 100 | 100 | 82 | 100 | 100 | 44 | |
| 13 | IPCA-D | [Rh(NBD)2]BF4 | MeOH | 20 | 50 | W002-2 | 100 | 100 | 74 | 25 | 100 | 34 | |
| 14 | IPCA-D | [Rh(NBD)2]BF4 | MeOH | 20 | 50 | W001-1 | 100 | 100 | 25 | 100 | 54 | ||
| 15 | IPCA-D | [RhCl(NBD)]2 | THF | 20 | 50 | W002-2 | 25 | 7 | n.d. | 25 | 21 | ||
| 16 | EOCA-D | [Rh(NBD)2]BF4 | MeOH | 20 | 3.5 | W002-2 | 25 | 100 | 80 | 25 | 100 | 19 | |
| 17 | EOCA-D | [Rh(NBD)2]BF4 | MeOH | 20 | 3.5 | W001-1 | 40 | 80 | 25 | 100 | 44 | ||
| 18 | EOCA-D | [RhCl(NBD)]2 | THF | 20 | 20 | W002-2 | 25 | 100 | 86 | 25 | 100 | 16 | |
| 19 | ACA | [RuI2(p-cymene)]2 | MeOH | 80 | 80 | W002-2 | 500 | 100 | 85 | 500 | 100 | 80 | |
| 20 | ACA | [RuI2(p-cymene)]2 | MeOH | 80 | 80 | W001-1 | 500 | 100 | 500 | 100 | |||
| 21 | EOP | [RuI2(p-cymene)]2 | EtOH | 80 | 80 | W002-2 | 100 | 100 | 76 | 100 | 94 | 33 | |
| 22 | EOP | [RuI2(p-cymene)]2 | EtOH | 80 | 80 | W001-1 | 100 | 100 | 100 | 100 | 75 |
HTS results.
Additive NaOMe.
Additive HCl.
Product Absolute Configurations Given for Walphos Ligands of R,RFc and Biferrocene Ligands of R,SFc,RFc Absolute Configuration
| entry | substrate | precursor | Walphos ligand | abs confign | BiFc ligand | abs confign |
|---|---|---|---|---|---|---|
| 1 | MAC | [Rh(NBD)2]BF4 | W002 | |||
| 2 | MAC | [Rh(NBD)2]BF4 | W001 | |||
| 3 | MAA | [Rh(NBD)2]BF4 | W002 | |||
| 4 | MAA | [Rh(NBD)2]BF4 | W001 | |||
| 5 | DMI | [Rh(NBD)2]BF4 | W002 | |||
| 6 | DMI | [Rh(NBD)2]BF4 | W001 | |||
| 7 | MCA | [Rh(NBD)2]BF4 | W002 | |||
| 8 | MCA | [Rh(NBD)2]BF4 | W001 | |||
| 9 | MCA | [RhCl(NBD)]2 | W002 | |||
| 10 | MCA | [RhCl(NBD)]2 | W002 | |||
| 11 | PCA | [Rh(NBD)2]BF4 | W002 | |||
| 12 | PCA | [Rh(NBD)2]BF4 | W001 | |||
| 13 | IPCA-D | [Rh(NBD)2]BF4 | W002 | |||
| 14 | IPCA-D | [Rh(NBD)2]BF4 | W001 | |||
| 15 | IPCA-D | [RhCl(NBD)]2 | W002 | |||
| 16 | EOCA-D | [Rh(NBD)2]BF4 | W002 | |||
| 17 | EOCA-D | [Rh(NBD)2]BF4 | W001 | |||
| 18 | EOCA-D | [RhCl(NBD)]2 | W002 | |||
| 19 | ACA | [RuI2( | W002 | |||
| 20 | ACA | [RuI2( | W001 | |||
| 21 | EOP | [RuI2( | W002 | |||
| 22 | EOP | [RuI2( | W001 |
Chart 4